Survival analysis of ovarian cancer patients with distant metastasis after chemotherapy: A SEER-based study

This study investigated the overall survival (OS) of patients with distant metastasis of ovarian cancer after chemotherapy and surgery, and explored differences in the survival of these patients with single-site metastasis.

We selected only patients with stage IV ovarian cancer who had undergone chemotherapy. Using GraphPad Prism 7 software and Kaplan-Meier survival analysis, we confirmed the factors that were meaningful for OS. Survival-related risk factors were compared using the Cox proportional hazards model.

Patients with lung, bone, and brain metastasis experienced shorter survival than patients with liver metastasis who underwent chemotherapy. Among patients with distant metastasis who underwent chemotherapy and surgery, patients with brain metastasis experienced longer survival than patients with liver metastasis, while patients with bone and lung metastasis presented shorter survival than patients with liver metastasis. Finally, surgery prolonged the survival of patients with stage IV ovarian cancer with single-site metastasis, who were treated with chemotherapy.

Chemotherapy combined with surgery significantly prolonged OS and cancer-specific survival (CSS) of patients with distant metastatic stage IV ovarian cancer. Lung metastasis resulted in a shorter survival than liver metastasis in patients treated with chemotherapy alone or in combination with surgery.